Zhi Tong Cai Jing·2025-09-18 02:34Core Viewpoint - Rongchang Biologics (09995) saw a stock increase of over 8%, currently trading at 115 HKD with a transaction volume of 222 million HKD, following the announcement of positive clinical trial data for its innovative drug, Tai Ai (RC18) [1] Group 1: Clinical Development - On September 18, Rongchang Biologics announced that its self-developed dual-target fusion protein drug, Tai Ai (RC18), has successfully entered the 2025 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting for a verbal presentation, showcasing data from a 48-week open-label extension study aimed at verifying long-term efficacy for generalized myasthenia gravis (gMG) [1] - The AANEM annual meeting will take place from October 29 to November 1, 2025, in San Francisco, California [1] Group 2: Strategic Partnerships - Recently, during an earnings briefing, the company revealed that in August 2021, it entered into a global exclusive licensing agreement with Seattle Genetics (now acquired by Pfizer Inc.) for the development and commercialization rights of Vidisicimab (RC48) outside of its designated regions, which exclude Japan and Singapore [1] - Currently, the clinical trials for RC48 are being advanced as planned by Pfizer in overseas markets [1]